(NYSE:MSB) Financial Results and Operational Update for the Full Year Ended June 30, 2025
Financial Results and Operational Update for the Full Year Ended June 30, 2025
Related Questions
What are the revised revenue and EPS guidance after the FDA approval and commercial launch of Ryoncil?
How does the expected market opportunity for Ryoncil compare to Mesoblast's other pipeline assets and to competitors in the same therapeutic area?
What are the implications for the company's cash runway and financing needs, and could there be dilution or debt issuance as a result?